Midatech Pharma plc
Index- P/E- EPS (ttm)-0.45 Insider Own0.14% Shs Outstand12.66M Perf Week1.89%
Market Cap13.06M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float12.55M Perf Month-38.23%
Income-6.70M PEG- EPS next Q- Inst Own5.10% Short Float0.02% Perf Quarter-46.32%
Sales0.70M P/S18.66 EPS this Y-3.90% Inst Trans- Short Ratio0.04 Perf Half Y-66.88%
Book/sh0.36 P/B1.50 EPS next Y- ROA-145.50% Target Price- Perf Year-73.53%
Cash/sh0.21 P/C2.56 EPS next 5Y- ROE-256.70% 52W Range0.38 - 3.61 Perf YTD-48.58%
Dividend- P/FCF- EPS past 5Y- ROI-312.30% 52W High-85.04% Beta2.40
Dividend %- Quick Ratio1.80 Sales past 5Y- Gross Margin- 52W Low42.08% ATR0.07
Employees18 Current Ratio1.80 Sales Q/Q-20.00% Oper. Margin- RSI (14)37.85 Volatility11.04% 12.65%
OptionableNo Debt/Eq0.22 EPS Q/Q83.00% Profit Margin- Rel Volume0.85 Prev Close0.54
ShortableYes LT Debt/Eq0.17 Earnings- Payout- Avg Volume53.25K Price0.54
Recom- SMA20-14.60% SMA50-31.33% SMA200-58.08% Volume0 Change0.00%
Apr-26-22 02:00AM  
Apr-14-22 08:10AM  
Mar-09-22 02:00AM  
Mar-08-22 05:00AM  
Jan-17-22 02:00AM  
Dec-13-21 05:20AM  
Nov-13-21 03:38AM  
Sep-06-21 02:00AM  
Jul-12-21 09:50AM  
Jun-29-21 09:01AM  
Jun-17-21 08:35AM  
Jun-09-21 02:00AM  
May-21-21 11:15AM  
May-17-21 04:35AM  
Apr-30-21 10:15AM  
Mar-25-21 07:58AM  
Feb-17-21 02:00AM  
Dec-11-20 12:15PM  
Nov-24-20 02:00AM  
Oct-19-20 02:00AM  
Sep-10-20 02:00AM  
Sep-07-20 06:20AM  
Aug-28-20 02:00AM  
Aug-19-20 02:00AM  
Aug-14-20 02:00AM  
Jul-23-20 02:00AM  
Jul-03-20 02:00AM  
Jun-30-20 09:40AM  
Jun-24-20 12:18PM  
Jun-17-20 02:00AM  
Jun-16-20 02:00AM  
Jun-09-20 11:35AM  
May-22-20 06:00AM  
May-21-20 02:01AM  
May-19-20 07:15AM  
May-18-20 10:20AM  
May-12-20 12:55PM  
May-01-20 07:00AM  
Apr-22-20 11:30AM  
Apr-20-20 01:10PM  
Mar-31-20 02:00AM  
Mar-02-20 11:25AM  
Feb-12-20 09:50AM  
Jan-08-20 08:12AM  
Dec-17-19 07:56AM  
Dec-16-19 06:20PM  
Dec-05-19 09:10AM  
Nov-14-19 05:54AM  
Oct-28-19 03:05AM  
Jul-19-19 03:24PM  
May-09-19 10:30AM  
Feb-27-19 10:00AM  
Jan-29-19 06:42AM  
Dec-11-18 03:17AM  
Oct-10-18 04:28AM  
Oct-03-18 11:00AM  
Sep-27-18 07:00AM  
Sep-18-18 06:36AM  
Sep-07-18 10:30AM  
Aug-31-18 07:00AM  
Jul-25-18 07:00AM  
Jul-23-18 09:23AM  
Jun-08-18 02:00AM  
May-29-18 02:51PM  
May-25-18 07:00AM  
May-03-18 08:20AM  
Apr-27-18 09:45AM  
Mar-23-18 03:32AM  
Mar-15-18 08:01AM  
Mar-07-18 10:15AM  
Feb-28-18 07:00AM  
Feb-14-18 07:00AM  
Jan-16-18 07:01AM  
Jan-12-18 12:00PM  
Nov-27-17 03:00PM  
Oct-27-17 01:59PM  
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.